Dimitri E. Grigoriadis, Neurocrine Biosciences's Chief Research Officer, recently disposed of 25,000 shares of the company. The disposals took place at $47.77 per share, on October 16, 2015. Grigoriadis still owns 105,308 shares of the company. Grigoriadis operates out of San Diego, CA. Some additional info was provided as follows:
Sale of 25,000 shares of common stock issued upon vesting of 50,000 restricted stock units on October 15, 2015 to cover payroll and withholding taxes, with the balance of the shares (25,000) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box
3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $46.61 to $49.84. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The above information was disclosed in a filing to the SEC. To see this filing in its entirety, click here. Neurocrine Biosciences next reports earnings on November 02, 2015.
To receive a free e-mail notification whenever Neurocrine Biosciences makes a similar move, sign up!
Other recent filings from the company include the following:
Neurocrine Biosciences Announces Topline Data From Phase Iib T-Force GOLD Study Demonstrating
Valbenazine Did Not Meet - Dec. 12, 2018
Neurocrine Biosciences's Chief Financial Officer just disposed of 1,178 shares - Dec. 6, 2018
Neurocrine Biosciences director just disposed of 4,124 shares - Nov. 27, 2018